Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: Comparison of the apoC-III to apoE ratio in different lipoprotein fractions

Journal of Lipid Research

Volumn 38, Issue 7, 1997, Pages 1421-1432

  Fredenrich, Alexandre ^a   Giroux, Louise Marie ^a   Tremblay, Michel ^a   Krimbou, Larbi ^a   Davignon, Jean ^a   Cohn, Jeffrey S ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Atherosclerosis; Cholesterol; FPLC; HDL; Remnants; Triglyceride

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E;

ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; APOLIPOPROTEINS E; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; REFERENCE VALUES; TRIGLYCERIDES;

EID: 0030750370     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Hodis, H. N., and W. J. Mack. 1995. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr. Opin. Lipidol. 6: 209-214.
2. Brewer, H. B., Jr., R. Shulman, P. Herbert, R. Ronan, and K. Wehrly. 1974. The complete amino acid sequence of alanine apolipoprotein (apoC-III), an apolipoprotein from human plasma very low density lipoproteins. J. Biol. Chem. 249: 4975-4984.
3. Lenich, C., P. Brecher, S. Makrides, A. Chobanian, and V. I. Zannis. 1988. Apolipoprotein gene expression in the rabbit: abundance, size, and distribution of apolipoprotein mRNA species in different tissues. J. Lipid Res. 29: 755-764.
4. Schonfeld, G., P. K. George, J. Miller, P. Reilly, and J. Witztum. 1979. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 28: 1001-1010.
5. Kashyap, M. L., L. S. Srivastava, B. A. Hynd, P. S. Gartside, and G. Perisutti. 1981. Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein C-III subspecies concentrations in hypertriglyceridemia. J. Lipid Res. 22: 800-810.
6. Malmendier, C. L., J. F. Lontie, C. Delcroix, D. Y. Dubois, T. Magot, and L. De Roy. 1989. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 77: 139-149.
7. Dammerman, M., L. A. Sandkuijl, J. L. Halaas, W. Chung, and J. L. Breslow. 1993. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc. Natl. Acad. Sci. USA. 90: 4562-4566.
8. Surguchov, A. P., G. P. Page, L. Smith, W. Patsch, and E. Boerwinkle. 1996. Polymorphic markers in apolipopotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 16: 941-947.
9. Shelburne, F., J. Hanks, W. Meyers, and S. A. Quarfordt. 1980. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J. Clin. Invest. 65: 652-658.
10. Windler, E., and R. J. Havel. 1985. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J. Lipid Res. 26: 556-563.
11. Brown, V., and M. L. Baginsky. 1972. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochim. Biophys. Acta. 46: 375-382.
12. Krauss, R. M., P. N. Herbert, R. I. Levy, and D. S. Fredrickson. 1973. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins. Circ. Res. 33: 403-411.
13. Wang, C-S., W. J. McConathy, H. U. Kloer, and P. Alaupovic. 1985. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75: 384-390.
14. McConathy, W. J., J. C. Gesquiere, H. Bass, A. Tartar, J-C. Fruchart, and C-S. Wang. 1992. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J. Lipid Res. 33: 995-1003.
15. Kinnenen, P. K. J., and C. Enholm. 1976. Effect of serum and C-apoproteins from very low density lipoproteins on human post-heparin plasma hepatic lipase. FEBS Lett. 65: 354-357.
16. Blankenhorn, D. H., P. Alaupovic, E. Wickham, H. P. Chin, and S. P. Azen. 1990. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 81: 470-476.
17. Hodis, H. N., W. J. Mack, S. P. Azen, P. Alaupovic, J. M. Pogoda, L. LaBree, L. C. Hemphill, D. M. Kramsch, and D. H. Blankenhorn. 1994. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90: 42-49.
18. Koren, E., C. Corder, G. Mueller, H. Centurion, G. Hallum, J. Fesmire, W. J. McConathy, and P. Alaupovic. 1996. Triglyceride-enriched lipoprotein particles correlate with severity of coronary artery disease. Atherosclerosis. 122: 105-115.
19. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice. Science. 249: 790-793.
20. Aalto-Setälä, K. E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apoC-III and reduced apoE on the particles. J. Clin. Invest. 90: 1889-1900.
21. Aalto-Setälä, K., P. H. Weinstock, C. L. Bisgaier, L. Wu, J. D. Smith, and J. L. Breslow. 1996. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse transgenic mice. J. Lipid Res. 37: 1802-1811.
22. Maeda, N., H. Li, D. Lee, P. Oliver, S. H. Quarfordt, and J. Osada. 1994. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biol. Chem. 269: 23610-23616.
23. de Silva, H. V., S. J. Lauer, J. Wang, W. S. Simonet, K. H. Weisgraber, R. W. Mahley, and J. M. Taylor. 1994. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J. Biol. Chem. 269: 2324-2335.
24. Mahley, R. W., and S. C. Rall, Jr. 1989. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill Publishing Co., New York, NY. 1195-1213.
25. Gibson, J. C., A. Rubinstein, P. R. Bukberg, and W. V. Brown. 1983. Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects. J. Lipid Res. 24: 886-898.
26. Castro, G. R., and C. J. Fielding. 1984. Evidence for the distribution of apolipoprotein E between lipoprotein classes in human normocholesterolemic plasma and for the origin of unassociated apolipoprotein E (Lp-E). J. Lipid Res. 25: 58-67.
27. Cohn, J. S., M. Tremblay, M. Amiot, D. Bouthillier, M. Roy, J. Genest, Jr., and J. Davignon. 1996. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Thromb. Vasc. Biol. 16: 146-159.
28. Bury, J., and M. Rosseneu. 1985. Enzyme-linked immunosorbent assay for human apolipoprotein C-III. J. Clin. Chem. Clin. Biochem. 23: 63-68.
29. Nakane, P., and J. Kawaoi. 1974. Peroxidase-labeled antibody. A new method of conjugation. J. Histochem. Cytochem. 22: 1084-1091.
30. Kricka, L. J., T. J. Carter, S. M. Burt, J. H. Kennedy, R. L. Holder, M. I. Halliday, M. E. Telford, and G. B. Wisdom. 1980. Variability in the adsorption properties of microtitre plates used as solid supports in enzyme immunoassay. Clin. Chem. 26: 741-744.
31. Curry, M. D., W. J. McConathy, J. D. Fesmire, and P. Alaupovic. 1980. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim. Biophys. Acta. 617: 503-513.
32. Hill, J. S., and P. H. Pritchard. 1990. Improved phenotyping of apolipoprotein E: application to population frequency distribution. Clin. Chem. 36: 1871-1874.
33. Chapman, M. J., P. M. Laplaud, G. Eue, P. Forgez, E. Bruckert, S. Goulinet, and D. Lagrange. 1988. Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J. Lipid Res. 29: 442-458.
34. Kandoussi, A., C. Cachera, D. Parsy, J. M. Bard, and J. C. Fruchart. 1991. Quantitative determination of different apolipoprotein B-containing lipoproteins by an enzyme-linked immunosorbent assay: apoB with apoC-III and apoB with apoE. J. Immunoassay. 12: 305-323.
35. Eisenberg, S., B. W. Bilheimer, F. T. Lindgren, and R. I. Levy. 1973. On the metabolic conversion of human very low density lipoprotein to low density lipoprotein. Biochim. Biophys. Acta. 326: 361-377.
36. Mjos, O. D., O. Faergeman, R. E. Hamilton, and R. J. Havel. 1975. Characterization of remnants produced during the metabolism of triglyceride-rich lipoproteins of blood plasma and intestinal lymph in the rat. J. Clin. Invest. 56: 603-615.
37. Pagnan, A., R. J. Havel, J. P. Kane, and E. Kotite. 1977. Characterization of human very low density lipoproteins containing two electrophoretic populations: double prebeta lipoproteinemia and primary dysbetalipoproteinemia. J. Lipid Res. 18: 613-622.
38. Havel, R. J., and J. P. Kane. 1973. Primary dysbetalipoproteinemia: predominance of a specific apoprotein species in triglyceride-rich lipoproteins. Proc. Natl. Acad. Sci. USA. 70: 2015-2019.
39. Havel, R. J., L. Kotite, J-L. Vigne, J. P. Kane, P. Tun, N. Phillips, and G. C. Chen. 1980. Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. Concentration in blood plasma and lipoproteins as affected by apoprotein E-3 deficiency. J. Clin. Invest. 66: 1351-1362.
40. Ehnholm, C., R. W. Mahley, D. A. Chappell, K. H. Weisgraber, E. Ludwig, and J. L. Witztum. 1984. Role of apolipoprotein E in the lipolytic conversion of β-very low density lipoproteins to low density in type III hyperlipoproteinemia. Proc. Natl. Acad. Sci. USA. 81: 5566-5570.
41. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257: 2518-2521.
42. Gregg, R. E., L. A. Zech, E. J. Schaefer, and H. B. Brewer, Jr. 1981. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 211: 584-586.
43. Sehayek, E., U. Lewin-Velvert, T. Chajek-Shaul, and S. Eisenberg. 1991. Lipolysis exposes unreactive endogenous apolipoprotein-E-3 in human and rat plasma very low density lipoprotein. J. Clin. Invest. 88: 553-560.
44. Sehayek, E., and S. Eisenberg. 1991. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266: 18259-18267.
45. Clavey, V., S. Lestavel-Delattre, C. Copin, J. M. Bard, and J. C. Fruchart. 1995. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII and E. Arterioscler. Thromb. Vasc. Biol. 15: 963-971.
46. Kowal, R. C., J. Herz, K. H. Weisgraber, R. W. Mahley, M. S. Brown, and J. L. Goldstein. 1990. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 10771-10779.
47. van Barlingen, H. H. J. J., H. de Jong, D. W. Erkelens, and T. W. A. de Bruin. 1996. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C. J. Lipid Res. 37: 754-763.
48. van Barlingen, H. H. J. J., L. A. W. Kock, F. H. A. F. de Man, D. W. Erkelens, and T. W. A. de Bruin. 1996. In vitro lipolysis of human VLDL: effect of different VLDL compositions in normolipidemia, familial combined hyperlipidemia and familial hypertriglyceridemia. Atherosclerosis. 121: 75-84.
49. Attman, P. O., P. Alaupovic, M. Tavella, and C. Knight-Gibson. 1996. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol. Dial. Transplant. 11: 63-69.
50. Alaupovic, P. 1981. David Rubinstein Memorial Lecture: The biochemical and clinical significance of the interrelationship between very low density and high density lipoproteins. Can. J. Biochem. 59: 565-579.
51. Gibson, J. C., R. B. Goldberg, A. Rubinstein, H. N. Ginsberg, W. V. Brown, S. Baker, B. I. Joffe, and H. C. Seftel. 1987. Plasma lipoprotein distribution of apolipoprotein E in familial hypercholesterolemia. Arteriosclerosis. 7: 401-407.
52. Blum, C. D., L. Aron, and R. Sciacca. 1980. Radioimmunoassay studies of human apolipoprotein E. J. Clin. Invest. 66: 1240-1250.
53. Rubinstein, A., J. C. Gibson, J. R. Paterniti, Jr., G. Kakis, A. Little, H. N. Ginsberg, and W. V. Brown. 1985. Effect of heparin-induced lipolysis on the distribution of apolipoprotein E among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase. J. Clin. Invest. 75: 710-721.
54. Lee, D. M., and P. Alaupovic. 1986. Apolipoproteins B, C-III and E in two major subpopulations of low-density lipoproteins. Biochim. Biophys. Acta. 879: 126-133.
55. Koren, E., P. Alaupovic, D. M. Lee, N. Dashti, H. U. Kloer, and G. Wen. 1987. Selective isolation of human plasma low-density lipoprotein particle containing apolipoprotein B and E by use of a monoclonal antibody to apolipoprotein B. Biochemistry. 26: 2734-2740.
56. Luc, G., C. Fievet, D. Arveiler, A. E. Evans, J-M. Bard, F. Cambien, J-C. Fruchart, and P. Ducimetiere. 1996. Apolipoprotein C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infraction: the ECTIM study. J. Lipid Res. 37: 508-517.
57. Nordestgaard, B. G. 1996. The vascular endothelial barrier - selective retention of lipoproteins. Curr. Opinion Lipidol. 7: 269-273.